At a glance
ClinicalIndex Comparison RecordPhase 2Active· 309 enrolled
Drug / intervention
Ramucirumab +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
In Brief
A Phase 2 clinical trial evaluating Ramucirumab, Merestinib, and 4 other interventions for Biliary Tract Cancer and 2 related conditions. Active but no longer recruiting, targeting 309 participants across 82 sites in 18 countries.
Detailed Summary
The main purpose of this study is to evaluate the efficacy and safety of ramucirumab or merestinib or placebo plus cisplatin and gemcitabine in participants with advanced or metastatic biliary tract cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBiliary Tract Cancer, Metastatic Cancer, Advanced Cancer
CountriesArgentina, Australia, Austria, Belgium, Czechia, Denmark, France, Germany, Hungary, Mexico, Russia, South Korea, Spain, Sweden, Taiwan, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 2Active
201620172018201920202021202220232024202520262027
First PostedMar 2016
Enrollment StartMay 2016
Primary CompletionFeb 2018
TodayJul 2026
Study CompletionDec 2026
First PostedMar 17, 2016
Enrollment StartMay 19, 2016
Primary CompletionFeb 16, 2018
Study CompletionDec 1, 2026
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 10.3 years ago
Interventions
Ramucirumabdrug
Administered IV
Merestinibdrug
Administered orally
Cisplatindrug
Administered IV
Gemcitabinedrug
Administered IV
Placebo Oraldrug
Administered orally
Placebo IVdrug
Administered IV